Letter: Breaking new ground-Understanding the role of ATI-free diet in managing MASLD-Authors' reply

Angelo Armandi^{1

2}, Detlef Schuppan^{3

4}, Jörn M Schattenberg^{2

5}

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Medical Sciences, University of Turin, Turin, Italy.
² Metabolic Liver Disease Research Program, I. Department of Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
³ University Medical Center, Institute of Translational Immunology and Research Center for Immunotherapy, Johannes Gutenberg-University, Mainz, Germany.
⁴ Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
⁵ Department of Internal Medicine II, Saarland University Medical Center, Homburg, Germany.

Comment

Angelo Armandi et al. Aliment Pharmacol Ther. 2024 Jul.

. 2024 Jul;60(2):304-305.

doi: 10.1111/apt.18119. Epub 2024 Jun 11.

Angelo Armandi^{1

2}, Detlef Schuppan^{3

4}, Jörn M Schattenberg^{2

5}

¹ Division of Gastroenterology and Hepatology, Department of Medical Sciences, University of Turin, Turin, Italy.
² Metabolic Liver Disease Research Program, I. Department of Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
³ University Medical Center, Institute of Translational Immunology and Research Center for Immunotherapy, Johannes Gutenberg-University, Mainz, Germany.
⁴ Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
⁵ Department of Internal Medicine II, Saarland University Medical Center, Homburg, Germany.

No abstract available

Comment on

Letter: Breaking new ground-Understanding the role of ATI-free diet in managing MASLD.
Spertino M, Elisa RR, Pugliese N. Spertino M, et al. Aliment Pharmacol Ther. 2024 Jul;60(2):302-303. doi: 10.1111/apt.18064. Epub 2024 Jun 11. Aliment Pharmacol Ther. 2024. PMID: 38860611 No abstract available.

1. Spertino M, Rossi RE, Pugliese N. Letter: Breaking new ground—understanding the role of ATI‐free diet in managing MASLD. Aliment Pharmacol Ther. 2024;60:302–303.
1. Armandi A, Bespaljko H, Mang A, Huber Y, Michel M, Labenz C, et al. Short‐term reduction of dietary gluten improves metabolic‐dysfunction associated steatotic liver disease: a randomised, controlled proof‐of‐concept study. Aliment Pharmacol Ther. 2024;59:1212–1222. https://doi.org/10.1111/apt.17941
1. Michel M, Doll M, Albert N, Morgenstern M, Behr A, Maxeiner S, et al. Obesity and harmful alcohol consumption are predictors for advanced liver disease in the disease management program for type 2 diabetes. United European Gastroenterol J. 2024;12(1):11–21. https://doi.org/10.1002/ueg2.12511
1. Tilg H, Adolph TE, Trauner M. Gut‐liver axis: pathophysiological concepts and clinical implications. Cell Metab. 2022;34(11):1700–1718. https://doi.org/10.1016/j.cmet.2022.09.017
1. Ashfaq‐Khan M, Aslam M, Qureshi MA, Senkowski MS, Yen‐Weng S, Strand S, et al. Dietary wheat amylase trypsin inhibitors promote features of murine non‐alcoholic fatty liver disease. Sci Rep. 2019;9:17463. https://doi.org/10.1038/s41598‐019‐53323‐x